Context Therapeutics Reports Encouraging Early Responses In Phase 1 Trial Of CTIM-76
Context Therapeutics (CNTX) reported interim Phase 1 results for CTIM-76 in heavily pretreated platinum-resistant ovarian cancer. As of May 29, 2026, at active doses of 140–280µg, 29% (2/7) of evaluable patients had confirmed partial responses and 57% (4/7) had disease control; some maintained benefit for 6+ months. CRS was Grade 1 in 11% of ovarian patients. The Phase 1a dose-escalation enrolled 21 patients; the 560µg dose was not advanced. CNTX plans Q3W dosing in 2H 2026 and Phase 1b in 2027.
Interim efficacy and tolerability data for CTIM-76 in heavily pretreated ovarian cancer can re-rate near-term clinical probability and sentiment.
Context Therapeutics reported interim Phase 1 CTIM-76 results with 29% confirmed partial responses and manageable Grade 1 CRS in ovarian cancer.
Likely positive bias for CNTX as traders price improved early signal; magnitude depends on follow-on Phase 1b/expansion details.
Background
CTIM-76 is in Phase 1a dose-escalation for heavily pretreated platinum-resistant ovarian cancer; the study includes multiple tumor types and is transitioning toward Q3W dosing.
Why it matters
Interim efficacy (confirmed partial responses and disease control) plus limited CRS at active doses can improve perceived clinical signal quality and de-risk early development, supporting expectations for the planned Q3W schedule and Phase 1b expansion.
Market relevance
Traders can update CNTX clinical-risk models based on newly disclosed interim response rates, dose-escalation outcomes, and CRS tolerability, with the next decision point tied to Q3W transition and Phase 1b start.
Market effects
Adds incremental evidence for T-cell engager-style oncology programs in platinum-resistant ovarian cancer, potentially supporting peer sentiment around early-phase readouts.
Primarily US biotech sentiment; limited direct regional spillover beyond clinical-trial risk appetite.
Oncology trial data can influence global biotech sentiment, but impact is likely localized to ovarian cancer/T-cell engager narratives.
Alternative perspectives
Phase 1a interim results are small (7 evaluable patients per cohort) and may not translate into durable benefit or Phase 2 success; safety signals could change at higher exposure or in expansion.
The article notes the highest dose exceeded target exposure and was not advanced; traders may discount efficacy if the optimal therapeutic window is unclear, and will watch for response durability beyond six months.
Key entities
- companyContext Therapeutics Inc.
Sponsor of CTIM-76; disclosed interim Phase 1a efficacy and safety data and plans for Q3W dosing and Phase 1b expansion.
- programCTIM-76
Investigational anti-tumor therapy evaluated in Phase 1a with interim response and CRS observations.
- regulatoryFDA Fast Track Designation
Fast Track designation for platinum-resistant ovarian cancer, reflecting unmet need and potential regulatory engagement.
